Linda Ann🇺🇸❤️🤍💙 รีทวีตแล้ว

🚨 Dr. William Makis just dropped his updated Ivermectin & Fenbendazole Cancer Protocol.
And people are losing their minds.
Not because it's controversial.
Because it gives real answers.
Here's the truth:
Most protocols treat every cancer the same.
Dr. Makis says that's a mistake.
A patient in remission ≠ a patient with widespread metastases.
A slow-growing tumor ≠ aggressive brain cancer.
So he designed FOUR dosing levels.
Not one. Four.
👇
🟢 LOW DOSE
Ivermectin: ≤ 0.5 mg/kg – 3x per week
Fenbendazole: 222 mg/day – 3 days on, 4 off
Best for: Remission support, prevention, strong family history, higher risk individuals.
🟡 MEDIUM DOSE
Ivermectin: 1.0 mg/kg – daily
Fenbendazole: 222 mg/day – 6 days per week
Best for: Most active cancers – common starting approach.
🔵 HIGH DOSE
Ivermectin: 2.0 mg/kg – daily
Fenbendazole: 444 mg/day – 6 days per week
Best for: Aggressive cancers, brain cancer, leukemia, pancreatic cancer.
🔴 VERY HIGH DOSE
Ivermectin: ≥ 2.5 mg/kg – daily
Fenbendazole: 888-1000 mg/day – 6 days per week
Best for: Extensive metastatic disease, poor prognosis cases.
💡 Why is this different?
It's not about the numbers.
It's about the thinking behind them.
Dr. Makis believes cancer isn't one disease. It's many.
And a one-size-fits-all approach?
That doesn't always make sense.
🔬 The research is growing.
Ivermectin and Fenbendazole are being studied for how they interact with:
• Cancer metabolism
• Cancer stem cells
• Mitochondrial function
• Tumor signaling pathways
• Treatment resistance mechanisms
• Cellular energy production
One thing is undeniable:
More cancer patients, caregivers, and researchers are talking about repurposed medicines today than ever before.
And that's exactly why charts like this keep getting shared.
📌 Save this chart.
Six months from now, you'll wish you knew where to find it.
🔁 Repost it. Someone researching cancer protocols needs to see this.
💬 Have you been following Dr. Makis' work?
#DrMakis #Ivermectin #Fenbendazole #CancerProtocol #RepurposedDrugs

English
























